|Day Low/High||61.26 / 62.70|
|52 Wk Low/High||45.76 / 67.16|
A potential breakthrough in Alzheimer's. A new device for blood pressure. More vaccines. These are opportunities to cheer in a time of turmoil.
Traders should stay long and consider increasing their exposure.
A correction in EBS could soon set up an attractive opportunity.
This Friday several banks begin the unofficial kickoff of 'earnings season'.
I am staying away from this name for now, despite the Alexion acquisition and vaccine promise.
BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.
The technical patterns of Boeing, Bristol-Myers Squibb and DraftKings are worth tracking for potential buys.
I am flat LLY for now. Let's see how the shares behave around the technicals. Then we'll make an equity decision.
The most important market takeaway right now is that both the Nasdaq Composite and S&P 500 have filled their respective gaps and retaken their 50-day simple moving averages.
These are the top five misconceptions about presidential elections -- and the stocks that you should look at right now.
The market is reflecting a triumph of big business over small business, and here's what that means for individual stocks.
Aggressive traders could go long BMY at two price levels.
Even more important than fiscal support moving forward would be the concept of Covid-19 very soon being effectively treatable for the public.
It's remarkable to see such excitement based on totally contradictory theories and themes.
BMY's announced acquisition of MyoKardia for $13B comes less than a year after its purchase of Celgene.
This diversification strategy lets you to capture stock market upside, while not risking your shirt.
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
The market's performance in the three months leading up to a presidential election has displayed an uncanny ability to forecast which party will win the White House.
BMY sees reason for optimism over the final half of the year.
Check out the Dow Transports and the Dow Industrials.
These pharmaceutical favorites continue to make progress on a number of fronts including a Covid-19 vaccine.
Many quality companies that fit into the socially responsible investing camp offer direct-purchase plans, allowing investors an easy way to build an SRI portfolio.
I like putting some of my money with incredibly successful folks who are well-connected and have a history of success.
The bullish reversal pattern is appearing not just in single names, but also in whole sectors.
As Treasury heads for longer-dated issuance and names like PTON run higher on earnings, selloffs late in the trading day continue.
The small biotech's market cap sits at $125 million, the low end of what I believe is fair.